Bioadaptives (BDPT) EBITDA Margin (2016 - 2026)

Bioadaptives has disclosed EBITDA Margin across 9 years of filings, most recently posting 3567.61% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 3567.61%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 4159.98% (up 11456683.0% YoY), and the FY2025 annual result was 5701.79%, down 94932.0% from the prior year.
• EBITDA Margin came in at 3567.61% for Q1 2026 at Bioadaptives, down from 2379.56% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 415.47% in Q1 2024 to a low of 13774.52% in Q2 2024.
• The 5-year median for EBITDA Margin is 2385.78% (2023), against an average of 3457.68%.
• Across the five-year window, EBITDA Margin tumbled 1138251 bps in 2024 and soared 510043 bps in 2025, its largest moves.
• Bioadaptives' EBITDA Margin stood at 685.29% in 2022, then declined by 25 bps to 857.99% in 2023, then tumbled by 1505 bps to 13774.52% in 2024, then jumped by 83 bps to 2379.56% in 2025, then slumped by 50 bps to 3567.61% in 2026.
• The last three EBITDA Margin figures came in at 3567.61% (Q1 2026), 2379.56% (Q4 2025), and 5735.95% (Q3 2025), per Business Quant data.